Related Experiment Video
Updated: Jun 25, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Antiangiogenic therapy for metastatic breast cancer: current status and future directions
1Mount Breast Group, Mount Hospital, Perth, Western Australia, Australia. arlene.chan@bigpond.com
Abstract:
The use of chemotherapy and endocrine therapy have led to objective tumour shrinkage and improved survival in women with metastatic breast cancer. Despite the availability of many chemotherapeutic drugs, these agents do not act specifically on the various growth signalling pathways that drive tumour growth and progression. This lack of specificity is likely to explain the inconsistent responses seen across the population of breast cancer patients and contributes to the undesirable adverse effects. The expanding knowledge of the important molecular pathways involved in tumourogenesis and tumour progression has led to the exciting development of several classes of targeted agents. The potential advantage of such treatment is to improve cancer cell kill with less damage to healthy tissues. Hormonal agents were the first to utilize the specific estrogen receptor-related growth pathways for therapeutic efficacy. Agents directed to the human epidermal growth factor receptor (HER)-2/neu growth signalling pathway exemplify the effectiveness of the new generation of targeted biological agents, but are limited to the 20-25% of breast cancers that overexpress the receptor. However, angiogenesis is a critical component of tumour development that is necessary for all tumour growth and is not limited to a subset of breast cancers. Therefore, agents that can diminish or prevent tumour angiogenesis are likely to have a far broader application and benefit to women with breast cancer. Several anti-angiogenic agents have been evaluated in phase I, II and III trials for patients with metastatic breast cancer. These trials have demonstrated efficacy of anti-angiogenic agents when used in combination with chemotherapy and the toxicity profile has been better defined. Issues regarding the mechanisms of resistance, identifying combination regimens that result in the greatest clinical benefits and minimizing the adverse effects are areas that require further research.
Insights
Targeted therapies offer improved breast cancer treatment by targeting specific pathways. Anti-angiogenic agents show broad potential by inhibiting tumour blood vessel formation, improving outcomes in metastatic breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Chemotherapy and endocrine therapy improve survival in metastatic breast cancer but lack specificity, causing side effects.
- Targeted agents exploit knowledge of molecular pathways for more specific cancer cell kill with less damage to healthy tissues.
- While hormonal agents and HER-2/neu targeted therapies are effective, their application is limited to specific patient subsets.
Purpose of the Study:
- To review the development and application of targeted agents in metastatic breast cancer treatment.
- To highlight the potential of anti-angiogenic agents due to their broad applicability across all breast cancers.
- To discuss the efficacy, safety, and future research directions for anti-angiogenic therapies in metastatic breast cancer.
Main Methods:
- Review of existing literature on chemotherapy, endocrine therapy, and targeted agents in metastatic breast cancer.
- Analysis of clinical trial data (Phase I, II, III) for anti-angiogenic agents in combination with chemotherapy.
- Evaluation of the benefits, limitations, and adverse effects of current and emerging targeted therapies.
Main Results:
- Targeted agents demonstrate improved specificity and reduced toxicity compared to traditional chemotherapy.
- Anti-angiogenic agents have shown efficacy when combined with chemotherapy in metastatic breast cancer.
- Clinical trials have better defined the toxicity profile of anti-angiogenic agents.
Conclusions:
- Targeted therapies, particularly anti-angiogenic agents, represent a significant advancement in metastatic breast cancer treatment.
- Anti-angiogenic agents offer a promising therapeutic strategy with broader applicability than receptor-specific targeted therapies.
- Further research is needed to address resistance mechanisms, optimize combination regimens, and minimize adverse effects of anti-angiogenic therapies.
More Related Videos
09:48Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
12:23Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound
Published on: August 14, 2012
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:10Mechanism of Angiogenesis
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:24Regulation of Angiogenesis and Blood Supply
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...